Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Total Neoadjuvant Therapy vs Standard Chemoradiation in LARC
NCT05274945Phase 2Completed
- Sponsor
- Alexandria University
- Start
- Jan 2020
- Primary completion
- Jan 2022
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of oxaliplatin, fluorouracil, capecitabine in rectal cancer, sponsored by Alexandria University. Started Jan 2020; status: completed.
02
Drugs
oxaliplatinfluorouracilcapecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05274945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05274945.